Federal Awards

Alto, Neal, NIH, Type III Effector Regulation of Host Signal Transduction Systems, $443,983; Baker, Linda, NIH, Prune Belly Syndrome, $368,881; Brekken, Rolf, NIH, Exploitation of RAS Signaling to Develop Therapy & Detection Strategies for PDA, $435,921; Carroll, Thomas, NIH, Interactions Between Stroma and Progenitor Cells During Kidney Development, $34,583; Chook, Yuh Min, NIH, Structures and Mechanisms of Nuclear Import and Export, $300,138; Cobb, Melanie (Fellow M. Kalwat), NIH, Role of Isoxazole Compounds In Beta Cell Differentiation and Function, $1,960; Collins, James, NIH, The Biology of Stem Cells in the Human Parasite Schistosoma Mansoni, $404,271;

Corey, David, NIH, Allele-Selective Inhibitors for Expanded Trinucleotide Repeat Genes, $292,997; Corey, David, NIH, Mechanism of RNA-Mediated Control of Transcription of Splicing, $257,580; Danuser, Gaudenz, Sanford-Burnham Medical Res Inst/NIH, Ultrastructural Basis of Mechanotransduction in Matrix Adhesions – Project 3, $206,018; Deberardinis, Ralph, St. Jude Children’s Res Hosp/NIH, Regulation of Erythropoiesis by the miR-144/451 MicroRNA Locus, $76,134; Elmquist, Joel, NIH, Leptin Action and Central Melanocortin Systems, $354,583; Elmquist, Joel (Fellow C. Castorena), NIH, Regulation of Energy Homeostasis via Cannabinoid 1 Receptors in the Ventral Media, $3,712;

Garcia, Christine, NIH, Mutant Surfactant Induced TGF-beta Secretion in Lung Fibrosis, $452,581; Ge, Wuping, NIH, Local Proliferation of Glia and Their Interaction with Blood Vessels, $237,905; Greenberg, Benjamin, Univ of California San Fran/NIH, Environmental & Genetic Risk Factors for Peds MS, $7,155; Greene, Robert, NIH, Glial Control of CNS State-Related Activity, $313,031; Hall, Christiana, Univ of Cincinnati/NIH, Ethnic/Racial Variation in Intracerebral Hemorrhage (Erich), $25,000; Herz, Joachim, NIH, Metabolism of the VLDL Receptor and ApoE Receptor, $400,229; Herz, Joachim, NIH, Molecular Basis of Synaptic Suppression by ApoE, $353,646;

Hobbs, Helen, NIH, Role of ABCG5 and ABCG8 in Sterol Metabolism, $468,454; Kavalali, Ege, NIH, Role of SNARE Interactions in Central Synapse Function, $397,500; Kennard, Beth, Johns Hopkins Univ/NIH, IMPAACT Management Oversight Group, $8,288; Kitchell, Ellen, Texas Dept of State Health Svc/CDC, HIV/PREVF HIV-Prevention Services, $200,800; Leavey, Patrick, Children’s Hosp Philadelphia/NIH, National Clinical Trials Network (NCTN), $27,550; Maldjian, Joseph, Wake Forest Univ Health Sciences/NIH, iTAKL: Imaging Telemetry & Kinematic-Modeling In Youth Football, $240,361; Mani, Ram, NIH, Tracing the Origins of Chromosomal Translocations in Prostate Cancer, $248,999;

Norgard, Michael, NIH, The RpoN-RpoS Regulatory Pathway in Borrelia Burgdorferi, $480,272; Norgard, Michael, NIH, Structure and Function of Treponema Pallidum Lipoproteins, $439,459; Pasare, Chandrashekhar, NIH, Role of BCAP in Regulating Inflammation and Adaptive Immunity, $404,271; Raskin, Philip, Univ of South Florida/NIH, TrialNet Affiliate Services, $16,765; Rogers, Zora, NIH, Baby HUG Follow-Up Study II, $174,495; Schiller, Joan, NIH, UT Southwestern NCI National Clinical Trials Network – YR2 Supplement, $50,000; Sherry, Dean, Duke Univ/NIH, Development of Novel Therapies for NIDDM: Core A, $159,000;

Snell, William, NIH, Cell Surface Recognition and Cell Interactions, $327,459; Sternweis, Paul, NIH, Signal Transduction Via Receptors and G Proteins, $442,928; Stowe, Ann, NIH, B Cells Alter Adaptive Autoimmunity to Protect from Ischemic Injury After Stroke, $353,737; Vinogradov, Elena, NIH, Endogenous Urea CEST MRI (urCEST): pH and Urea Gradient Mapping in Human Kidney, $202,135; Vongpatanasin, Wanpen, NIH, Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension, $550,995;

Wang, Jing, NIH, Next Generation 4D-CBCT for Lung Cancer Radiation Therapy, $36,375; Wang, Yingfei, NIH, The Role of a Novel AIF-associated Nuclease PAAN1 in Neuronal Injury, $24,901; Yan, Nan, NIH, HIV Subversion of Innate Immunity, $429,050; Zhang, Chengcheng, NIH, Role of Inhibitory Receptors in Leukemia Development, $329,925; Zhang, Rong, NIH, Exercise and Intensive Vascular Risk Reduction in Preventing Dementia, $2,540,442.

Nonfederal Awards

Beutler, Bruce (Fellow E. Turer), Crohn’s & Colitis Foundation of America, Genetic Analysis of Gastrointestinal Inflammation Through ENU Mutagenesis, $58,250; Cobb, Melanie (Fellow H. Dbouk), Amer Heart Assoc SW, Characterization of WNK1-PI3-Kinase Interaction and its Role in Endothelial Cell, $49,340; Collins, Robert, Oregon Health & Science Univ/Leukemia & Lymphoma Soc, Beat AML: Personalized Medicine for AML Based on Functional Genomics, $69,985; Dellinger, Michael, Lymphatic Malformation Inst, Characterization of a Mouse Model of Gorham-Stout Disease, $138,174; Elmquist, Joel (Fellow C. Liu), American Assoc SW, PARgamma in Vagal Neurons and the Clinical Effects of Thiazolidinediones, $70,000; Frohman, Elliot, New York Univ School of Med/Natl Multiple Sclerosis Soc, Mechanisms of Retinal Neurodegeneration and Visual Pathway Axonal Loss in MS, $48,301;

Gupta, Rana, Amer Heart Assoc SW, Investigating the Role of Adipocyte Hyperplasia in the Development of Lipotoxicity, $70,000; Gupta, Rana (Fellow M. Shao), Amer Heart Assoc SW, Adipose Zfp423 in the Control of Cardiometabolic Disease, $50,432; Hill, Joseph (Fellow G. Cho), Amer Heart Assoc SW, Reperfusion Injury Rescue by Tat-Beclin-Dependent Regulation of Cardiomyocyte Autophagy, $52,820; Holland, William, Juvenile Diabetes Res Fdn, Glucagon Receptor Antagonism in Beta Cell Survival and Proliferation, $350,000; Hsieh, Jer-Tsong (Fellow U. Lo), American Urological Assoc, A New MicroRNA Biogenesis Machinery Mediated by IFIT5 Complex Leading to Metastas Progression of Prostate Cancer, $40,000; Jain, Raksha, Cystic Fibrosis Fdn, Adult Therapeutics Development Network Additional Research Coordinator Award, $80,056;

Klesse, Laura, Children’s Tumor Fdn, Developing Evidence-Based Criteria for Initiating Treatment for NF1-OPG, $1,800; Rollins, Nancy, Columbia Univ/St. Baldrick’s Fdn, Biological Substrates of Impaired Neurocognitive Functioning, $31,367; Scaglioni, Pier, American Cancer Soc, Identification of Critical Components of the K-RAS Network in Lung Cancer, $180,000; Sharma, Preeti, Cystic Fibrosis Fdn, Mental Health Coordinator, $53,835; Shay, Jerry, Cystic Fibrosis Fdn, Genomic Editing of Normal and CF Human Lung Epithelial Cells, $81,000;

Stowe, Ann, Amer Heart Assoc Natl, B Cells Mediate Endogenous Neurovascular Protection Following Stroke, $77,000; Tandon, Animesh, Thrasher Res Fund, Predictive Analytics in Interstage Patients, $21,400; Yu, Hongtao, Clayton Fdn For Res, Development of Next Generation Antimitotic Anticancer Drugs, $300,000; Zhong, Qing (Fellow M. Cao), Amer Heart Assoc SW, The Molecular Link Between Primary Ciliogenesis and Heart Development, $50,432; Zhou, Xiaorong, Lung Cancer Res Fdn, Molecular Characterization of PCDH7/SET Pathway in Non-Small-Cell Lung Cancer, $75,000; Zigman, Jeffrey, Obesity Soc, Physiological Significance and Pharmacological Potential of Ligand-Independent (Constitutive) Ghrelin Receptor Activity, $45,000.

Industry Sponsored Awards, dollar amounts not available

Blomkalns, Andra, Study to Characterize the Management of Pts with Hyperkalemia Admitted to the Emergency Room, ZS Pharma; Chin, Kelly, Study of Transition from Inhaled Tresprostinil to Oral Selexipag in Adults with Pulmonary Arterial Hypertension, Quintiles Inc/Actelion Pharma; Dimas, Vasiliki, Nit-Occlud PDA Post-Approval Study, PFM Medical; Garg, Abhimanyu, Phase 2/3 Study of ISIS 304801 for Pts with Partial Lipodystrophy, Medpace/Isis Pharma; Gerber, David, Phase 3 Trial of Nivolumab vs. Platinum Doublet Chemo in Sbjc with Chemo-Naive Stage IV or Recurrent NSCLC, Bristol-Myers Squibb; Huang, Chou-Long, Proposal to Characterize Bioactivity of Recombinant Klot, Boehringer Ingelheim Pharma;

Jain, Raksha, Phase 2 Study of JBT-101 in Cystic Fibrosis, Corbus Pharma; Lee, William, Phase 2 Study of MK-3682B for Chronic HCV GT1 or GT3 Infection Who Failed Direct Acting Antiviral — MK3682-021-001, DrugDev/Merck Sharp & Dohme; McCavit, Timothy, Study of RTH258 Vs. Aflibercept for Age-Related Macular Degeneration, Alcon Research; Meyer, Jeffrey, Evaluation of Targeted Radiofrequency Ablation and Vertebral Augmentation for Radiation Therapy on Painful Metastatic Vertebral Body Tumors, Dfine Inc; Nations, Sharon, Extn of CBYM338B2203 Phase 2B/3 Study of Intravenous BYM338 for Sporadic Inclusion Body Myositis, Novartis Pharma; Patel, Vishal, Exploratory Studies in Autosomal Dominant Polycystic Kidney Disease (ADPKD), Regulus Therapeutics;

Ruggiero, Rosechelle, Medically Ill Patient Assessment of Rivaroxaban in Reducing Post-Discharge Venous Throbo-Embolism Risk (Mariner), Parexel Intl/Janssen; Shen, Paul, Phase 1/2A Escalation Study of Long-Acting Recombinant Factor VIIA (MOD-5014) in Adult Men with Hemophilia A or B, Opko Biologics; Vusirikala, Madhuri, Phase 3 Study of Lenalidomide plus R-CHOP Chemotherapy for Prev. Untreated Activated B-Cell Type Diffuse Large B-Cell Lymphoma, PPD Inc/Celgene Corp; Westover, Kenneth, Development of Covalent K-Ras Inhibitors, Dana-Farber Cancer Inst; Wu, Richard, Reduction of Radiation Dose during Cryoballoon Pulmonary Vein Isolation, Medtronic Inc; Zuniga, John, Evaluation of Digitally Reconstructed Radiographs (DRR), Autonomic Technologies.

Federal Awards – January 2016

Alto, Neal, NIH, Type III effector regulation of host signal transduction systems, $443,983; Baker, Linda, NIH, Prune Belly Syndrome, $368,881; Brekken, Rolf, NIH, Exploitation of RAS signaling to develop therapy & detection strategies for PDA, $435,921; Carroll, Thomas, NIH, Interactions Between Stroma and Progenitor Cells During Kidney Development, $34,583; Chook, Yuh Min, NIH, Structures and Mechanisms of Nuclear Import and Export, $300,138; Cobb, Melanie (Fellow M. Kalwat), NIH, Role of isoxazole compounds in beta cell differentiation and function, $1,960; Collins, James, NIH, The Biology of Stem Cells in the Human Parasite Schistosoma Mansoni, $404,271; Corey, David, NIH, Allele-Selective Inhibitors for Expanded Trinucleotide Repeat Genes, $292,997; Corey, David, NIH, Mechanism of RNA-Mediated Control of Transcription of Splicing, $257,580; Danuser, Gaudenz, SANFORD-BURNHAM MEDICAL RES INST/NIH, Ultrastructural Basis of Mechanotransduction in Matrix Adhesions – Project 3, $206,018;

Deberardinis, Ralph, ST. JUDE CHILDREN'S RES HOSP/NIH, Regulation of erythropoiesis by the miR-144/451 microRNA locus, $76,134; Elmquist, Joel, NIH, Leptin Action and Central Melanocortin Systems, $354,583; Elmquist, Joel (Fellow C. Castorena), NIH, Regulation of Energy Homeostasis via Cannabinoid 1 Receptors in the Ventral Media, $3,712; Garcia, Christine, NIH, Mutant Surfactant Induced TGF-beta Secretion in Lung Fibrosis, $452,581; Ge, Wuping, NIH, Local Proliferation of Glia and their Interaction with Blood Vessels, $237,905; Greenberg, Benjamin, UNIV OF CALIFORNIA, SAN FRANCISCO/NIH, Environmental & Genetic Risk Factors for Peds MS, $7,155; Greene, Robert, NIH, Glial Control of CNS State-Related Activity, $313,031; Hall, Christiana, UNIV OF CINCINNATI/NIH, Ethnic/Racial Variation in Intracerebral Hemorrhage (ERICH), $25,000; Herz, Joachim, NIH, Metabolism of the VLDL receptor and ApoE receptor, $400,229; Herz, Joachim, NIH, Molecular Basis of Synaptic Suppression by ApoE, $353,646;

Hobbs, Helen, NIH, Role of ABCG5 and ABCG8 in Sterol Metabolism, $468,454; Kavalali, Ege, NIH, Role of SNARE Interactions in Central Synapse Function, $397,500; Kennard, Beth, JOHNS HOPKINS UNIV/NIH, IMPAACT Management Oversight Group, $8,288; Kitchell, Ellen, TX DEPT OF STATE HEALTH SVC/CDC, HIV/PREVF HIV- Prevention Services, $200,800; Leavey, Patrick, CHILDREN'S HOSP PHILADELPHIA/NIH, National Clinical Trials Network (NCTN), $27,550; Maldjian, Joseph, WAKE FOREST UNIV HEALTH SCIENCES/NIH, iTAKL: Imaging Telemetry & Kinematic-Modeling In Youth Football, $240,361; Mani, Ram, NIH, Tracing the origins of chromosomal translocations in prostate cancer, $248,999; Norgard, Michael, NIH, The RpoN-RpoS regulatory pathway in Borrelia burgdorferi, $480,272; Norgard, Michael, NIH, Structure and Function of Treponema Pallidum Lipoproteins, $439,459; Pasare, Chandrashekhar, NIH, Role of BCAP in regulating inflammation and adaptive immunity, $404,271;

Raskin, Philip, UNIV OF SOUTH FLORIDA/NIH, TrialNet Affiliate Services, $16,765; Rogers, Zora, NIH, Baby HUG Follow-Up Study II, $174,495; Schiller, Joan, NIH, UT Southwestern NCI National Clinical Trials Network - YR2 Supplement, $50,000; Sherry, Dean, DUKE UNIV/NIH, Development of Novel Therapies for NIDDM: Core A, $159,000; Snell, William, NIH, Cell Surface Recognition and Cell Interactions, $327,459; Sternweis, Paul, NIH, Signal Transduction Via Receptors and G Proteins, $442,928; Stowe, Ann, NIH, B cells alter adaptive autoimmunity to protect from ischemic injury after stroke, $353,737; Vinogradov, Elena, NIH, Endogenous Urea CEST MRI (urCEST): pH and urea gradient mapping in human kidney, $202,135; Vongpatanasin, Wanpen, NIH, Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension, $550,995; Wang, Jing, NIH, Next generation 4D-CBCT for lung cancer radiation therapy, $36,375;

Wang, Yingfei, NIH, The role of a novel AIF-associated nuclease PAAN1 in neuronal injury, $24,901; Yan, Nan, NIH, HIV Subversion of Innate Immunity, $429,050; Zhang, Chengcheng, NIH, Role of Inhibitory Receptors in Leukemia Development, $329,925; Zhang, Rong, NIH, Exercise and Intensive Vascular Risk Reduction in Preventing Dementia, $2,540,442.

Non-Federal Awards – January 2016

Beutler, Bruce (Fellow E. Turer), CROHN'S & COLITIS FDN OF AMERICA, Genetic Analysis of Gastrointestinal Inflammation Through ENU Mutagenesis, $58,250; Cobb, Melanie (Fellow H. Dbouk), AMERICAN HEART ASSOC SW, Characterization of WNK1-PI3-Kinase Interaction and its Role in Endothelial Cell, $49,340; Collins, Robert, OREGON HEALTH & SCIENCE UNIV/LEUKEMIA & LYMPHOMA SOC, Beat AML: Personalized Medicine for AML based on Functional Genomics, $69,985; Dellinger, Michael, LYMPHATIC MALFORMATION INST, Characterization of a mouse model of Gorham-Stout Disease, $138,174; Elmquist, Joel (Fellow C. Liu), AMERICAN HEART ASSOC SW, PPARgamma in vagal neurons and the clinical effects of Thiazolidinediones, $70,000; Frohman, Elliot, NEW YORK UNIV SCH OF MED/NATL MULTIPLE SCLEROSIS SOC, Mechanisms of retinal neurodegeneration and visual pathway axonal loss in MS, $48,301;

Gupta, Rana, AMERICAN HEART ASSOC SW, Investigating the Role of Adipocyte Hyperplasia in the Development of Lipotoxicity, $70,000; Gupta, Rana (Fellow M. Shao), AMERICAN HEART ASSOC SW, Adipose Zfp423 in the Control of Cardiometabolic Disease, $50,432; Hill, Joseph (Fellow G. Cho), AMERICAN HEART ASSOC SW, Reperfusion Injury Rescue by Tat-Beclin-dependent Regulation of Cardiomyocyte Autophagy, $52,820; Holland, William, JUVENILE DIABETES RES FDN, Glucagon Receptor Antagonism in Beta Cell Survival and Proliferation, $350,000; Hsieh, Jer-Tsong (Fellow U. Lo), AMERICAN UROLOGICAL ASSOC, A new microRNA biogenesis machinery mediated by IFIT5 complex leading to metastas progression of prostate cancer , $40,000; Jain, Raksha, CYSTIC FIBROSIS FDN, Adult Therapeutics Development Network Additional Research Coordinator Award, $80,056; Klesse, Laura, CHILDREN'S TUMOR FDN, Developing Evidence-Based Criteria for Initiating Treatment for NF1-OPG, $1,800;

Rollins, Nancy, COLUMBIA UNIV/ST. BALDRICK'S FDN, Biological Substrates of Impaired Neurocognitive Functioning, $31,367; Scaglioni, Pier, AMERICAN CANCER SOC, Identification of critical components of the K-RAS network in lung cancer, $180,000; Sharma, Preeti, CYSTIC FIBROSIS FDN, Mental Health Coordinator, $53,835; Shay, Jerry, CYSTIC FIBROSIS FDN, Genomic editing of normal and CF human lung epithelial cells, $81,000; Stowe, Ann, AMERICAN HEART ASSOC NATL, B cells mediate endogenous neurovascular protection following stroke, $77,000; Tandon, Animesh, THRASHER RES FUND, Predictive Analytics in Interstage Patients, $21,400; Yu, Hongtao, CLAYTON FDN FOR RES, Development of Next Generation Antimitotic Anticancer Drugs, $300,000; Zhong, Qing (Fellow M. Cao), AMERICAN HEART ASSOC SW, The Molecular Link between Primary Ciliogenesis and Heart Development, $50,432; Zhou, Xiaorong, LUNG CANCER RES FDN, Molecular characterization of PCDH7/SET pathway in non-small-cell lung cancer, $75,000; Zigman, Jeffrey, OBESITY SOC, Physiological significance and pharmacological potential of ligand-independent (Constitutive) Ghrelin Receptor Activity, $45,000.

Industry Sponsored Awards, dollar amounts not available – January 2016

Blomkalns, Andra, Study to Characterize the Management of Pts with Hyperkalemia Admitted to the Emergency Room, ZS PHARMA; Chin, Kelly, Study of Transition from inhaled tresprostinil to oral selexipag in adults with pulmonary arterial hypertension, QUINTILES INC/ACTELION PHARMA; Dimas, Vasiliki, Nit-Occlud PDA Post-Approval Study, PFM MEDICAL; Garg, Abhimanyu, Phase 2/3 Study of ISIS 304801 for Pts with Partial Lipodystrophy, MEDPACE/ISIS PHARMA; Gerber, David, Phase 3 Trial of Nivolumab vs. Platinum Doublet Chemo in Sbjc with Chemo-Naive Stage IV or Recurrent NSCLC, BRISTOL-MYERS SQUIBB; Huang, Chou-Long, Proposal to Characterize Bioactivity of Recombinant Klot, BOEHRINGER INGELHEIM PHARMA; Jain, Raksha, Phase 2 Study of JBT-101 in Cystic Fibrosis, CORBUS PHARMA; Lee, William, Phase 2 Study of MK-3682B for Chronic HCV GT1 or GT3 Infection who failed Direct Acting Antiviral - MK3682-021-001, DrugDev/MERCK SHARP & DOHME; McCavit, Timothy, Study of RTH258 Vs. Aflibercept for Age-Related Macular Degeneration, ALCON RESEARCH;

Meyer, Jeffrey, Evaluation of Targeted Radiofrequency Ablation and Vertebral Augmentation for Radiation Therapy on Painful Metastatic Vertebral Body Tumors, DFINE INC; Nations, Sharon, Extn of CBYM338B2203 Phase 2B/3 Study of intravenous BYM338 for sporadic inclusion body myositis, NOVARTIS PHARMA; Patel, Vishal, Exploratory Studies in Autosomal Dominant Polycystic Kidney Disease (ADPKD), REGULUS THERAPEUTICS; Ruggiero, Rosechelle, Medically Ill Patient Assessment of Rivaroxaban in Reducing Post-Discharge Venous Throbo-Embolism Risk (MARINER), PAREXEL INTL/JANSSEN; Shen, Paul, Phase 1/2A Escalation Study of Long-Acting Recombinant Factor VIIA (MOD-5014) in Adult Men with Hemophilia A or B, OPKO BIOLOGICS; Vusirikala, Madhuri, Phase 3 Study of Lenalidomide plus R-CHOP Chemotherapy for Prev. Untreated Activated B-Cell Type Diffuse Large B-Cell Lymphoma, PPD INC/CELGENE CORP;

Westover, Kenneth, Development of Covalent K-Ras Inhibitors, DANA-FARBER CANCER INST; Wu, Richard, Reduction of Radiation Dose during Cryoballoon Pulmonary Vein Isolation, MEDTRONIC INC; Zuniga, John, Evaluation of Digitally Reconstructed Radiographs (DRR), AUTONOMIC TECHNOLOGIES.